AKT1 and prostate carcinoma: We have previously reported that the expression and activation of the PI3K/Akt cascade influences the progression to castrate resistant disease using clinical prostate cancer tumours, where phosphorylation of AR at the Akt consensus site serine 213 was significantly associated with disease progression [14,15].